株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

世界の尿路感染治療市場:2017〜2021年

Global Urinary Tract Infection Treatment Market 2017-2021

発行 TechNavio (Infiniti Research Ltd.) 商品コード 541317
出版日 ページ情報 英文 78 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.53円で換算しております。
Back to Top
世界の尿路感染治療市場:2017〜2021年 Global Urinary Tract Infection Treatment Market 2017-2021
出版日: 2017年08月09日 ページ情報: 英文 78 Pages
概要

世界の尿路感染治療市場は、2017〜2021年にかけCAGR2.15%で拡大すると予測されています。尿路感染は泌尿器系の影響を受ける部分によって様々なタイプに分類されます。女性の方が男性と比べて尿道が狭く肛門に近いため、男性と比べ尿路感染発症のリスクが高くなっています。

当レポートでは、世界の尿路感染治療市場について調査し、市況と疾患別、地域別動向、市場に参入する主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 当レポートの範囲

第3章 調査方法

第4章 イントロダクション

第5章 市況

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第6章 パイプライン分析

第7章 疾患別市場セグメンテーション

  • 非複雑性尿路感染
  • 複雑性尿路感染

第8章 地域別セグメンテーション

  • 地域別市場
  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋地域

第9章 意思決定の枠組み

第10章 促進因子と課題

第11章 市場動向

  • 抗生剤の使用管理に対する意識向上
  • スーパーバグ/MDR微生物に対する効果的治療のための研究開発
  • 尿路感染治療のための新たな治療法の探求

第12章 ベンダー環境

第13章 主要ベンダー分析

  • Bayer
  • Johnson & Johnson
  • Merck
  • Novartis
  • その他の注目すべきベンダー

第14章 付録

目次
Product Code: IRTNTR14167

About Urinary Tract Infection Treatment

UTI is an infection occurred in any part of the urinary system. The infection mostly involves the lower part of the urinary tract. UTI can be classified into different types depending on the portion of the urinary system affected. Women are comparatively at a higher risk of developing UTI as compared with men since the urethra of the women is comparatively smaller than men and is also closer to the anus. This anatomical structure of the urinary tract in women increases the chances of transfer of the bacteria to the bladder. However, people of any sex and age can get affected by the disease.

Technavio's analysts forecast the global urinary tract infection treatment market to grow at a CAGR of 2.15% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global urinary tract infection treatment market for 2017-2021. To calculate the market size, the report considers the sales of branded, off-label, and generic drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Urinary Tract Infection Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Merck,
  • Bayer,
  • Johnson & Johnson,
  • Novartis

Other Prominent Vendors

  • Achaogen
  • Allergan
  • Aquinox Pharmaceuticals
  • AstraZeneca
  • Lipella Pharmaceuticals
  • MediciNova
  • MerLion Pharma
  • Mylan
  • Novo Nordisk
  • Shionogi
  • Sun Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Urigen
  • Zavante Therapeutics

Market driver

  • Relation of UTI with several other factors leading to rising incidence rate of UTI
  • For a full, detailed list, view our report

Market challenge

  • Development of antibacterial resistance
  • For a full, detailed list, view our report

Market trend

  • Growing awareness of controlled usage of antibiotics
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Pipeline analysis

PART 07: Market segmentation by disease type

  • Uncomplicated UTI
  • Complicated UTI

PART 08: Geographical segmentation

  • UTI treatment market in Americas
  • UTI treatment market in EMEA
  • UTI treatment market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges

  • Market drivers
  • Market challenges

PART 11: Market trends

  • Growing awareness of controlled usage of antibiotics
  • Rising R&D for effective treatment against superbugs/MDR microorganisms
  • Advent of new therapies for UTI treatment

PART 12: Vendor landscape

PART 13: Key vendor analysis

  • Bayer
  • Johnson & Johnson
  • Merck
  • Novartis
  • Other prominent vendors

PART 14: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: UTI in various parts of the urinary tract
  • Exhibit 02: Symptoms, diagnosis, and treatment of UTI
  • Exhibit 03: Common medications used for the treatment of UTI
  • Exhibit 04: Global UTI treatment market snapshot
  • Exhibit 05: Global UTI treatment market 2016-2021 ($ millions)
  • Exhibit 06: Opportunity analysis of global UTI treatment market
  • Exhibit 07: Five forces analysis
  • Exhibit 08: Key pipeline molecules by vendors
  • Exhibit 09: Global UTI treatment market: Key clinical trials
  • Exhibit 10: Segmentation of global UTI treatment market by disease type 2016
  • Exhibit 11: Causative organisms for uncomplicated UTI
  • Exhibit 12: Global uncomplicated UTI treatment market 2016-2021 ($ millions)
  • Exhibit 13: Risk factors for uncomplicated UTI
  • Exhibit 14: Management of uncomplicated UTI through antimicrobial agents
  • Exhibit 15: Causative organisms for complicated UTI
  • Exhibit 16: Global complicated UTI treatment market 2016-2021 ($ millions)
  • Exhibit 17: Risk factors for complicated UTI
  • Exhibit 18: Segmentation of global UTI treatment market based on geography 2016 and 2021
  • Exhibit 19: Global UTI treatment market revenue by geography 2016-2021 ($ millions)
  • Exhibit 20: Market scenario in Americas
  • Exhibit 21: UTI treatment market in Americas 2016-2021 ($ millions)
  • Exhibit 22: Market scenario in EMEA
  • Exhibit 23: UTI treatment market in EMEA 2016-2021 ($ millions)
  • Exhibit 24: Market scenario in APAC
  • Exhibit 25: UTI treatment market in APAC 2016-2021 ($ millions)
  • Exhibit 26: Major factors contributing to UTI
  • Exhibit 27: New cases of diabetes by 2040
  • Exhibit 28: Accepted indications for catheter use
  • Exhibit 29: Major causes of antibiotic resistance
  • Exhibit 30: Competitive structure analysis of global UTI treatment market 2016
  • Exhibit 31: Bayer: Key highlights
  • Exhibit 32: Bayer: Strength assessment
  • Exhibit 33: Bayer: Strategy assessment
  • Exhibit 34: Bayer: Opportunity assessment
  • Exhibit 35: Johnson & Johnson: Key highlights
  • Exhibit 36: Johnson & Johnson: Strength assessment
  • Exhibit 37: Johnson & Johnson: Strategy assessment
  • Exhibit 38: Johnson & Johnson: Opportunity assessment
  • Exhibit 39: Merck: Key highlights
  • Exhibit 40: Merck: Strength assessment
  • Exhibit 41: Merck: Strategy assessment
  • Exhibit 42: Merck: Opportunity assessment
  • Exhibit 43: Novartis: Key highlights
  • Exhibit 44: Novartis: Strength assessment
  • Exhibit 45: Novartis: Strategy assessment
  • Exhibit 46: Novartis: Opportunity assessment
Back to Top